Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update May 20, 2021 08:00 ET | Source: Replimune Group Inc Replimune Group Inc Woburn, Massachusetts, UNITED STATES Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study Data update on lead programs to be provided du...
Source: globenewswire.com